Description
Prostamax
Product is sold for prescriber purposes only. Please handle with care and follow all safety guidelines for the specific chemicals involved.
Prostamax is a peptide bioregulator derived from prostate tissue, developed as part of the peptide therapy class originally pioneered by the Russian Institute of Bioregulation and Gerontology. Prostamax is composed of short peptide chains that act selectively on prostate tissue to support cellular function, regeneration, and immune modulation. It is primarily studied for its potential role in managing prostate disorders, such as benign prostatic hyperplasia (BPH), prostatitis, and age-related prostate dysfunction.
In laboratory rats, Prostamax has been shown to influence prostate health by modulating gene expression, reducing inflammatory markers, and stimulating the regeneration of epithelial tissue within the prostate gland. One study demonstrated that rats treated with Prostamax showed significant normalization of prostate gland structure and improved epithelial cell morphology compared to control groups. These findings suggest potential utility in age-related or hormone-induced prostatic changes [1].
Another study evaluating Prostamax in a model of chemically induced prostatitis revealed a marked decrease in pro-inflammatory cytokines such as IL-6 and TNF-alpha. This suggests that Prostamax may have anti-inflammatory properties that contribute to its therapeutic effect in chronic prostatitis and prostate tissue damage [2].
Furthermore, Prostamax appears to exert a regulatory effect on apoptosis-related genes, helping to balance cell proliferation and programmed cell death. In aging rats, Prostamax improved prostate histological parameters and reduced fibrosis, suggesting a restorative effect on senescent tissue [3].
While the research in animal models is promising, further clinical trials are needed to establish its efficacy and safety in humans. Nonetheless, Prostamax holds potential as a therapeutic agent in managing prostate health through peptide-based regenerative approaches.
References:
- Khavinson, V.K., et al. (2003). Peptide regulation of age-related changes in the prostate gland. Bulletin of Experimental Biology and Medicine, 136(7), 680–682. PubMed: 14635991
- Trofimova, S.V., et al. (2010). Effects of peptide bioregulators on experimental prostatitis in rats. Advances in Gerontology, 23(3), 432–437. PubMed: 21086525
- Khavinson, V.K., et al. (2012). Short peptides and prostate function in aging rats. Neuroendocrinology Letters, 33(6), 561–566. PubMed: 23391984
